Literature DB >> 20081811

Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases.

Sonja Klebe1, Noel A Brownlee, Annabelle Mahar, James L Burchette, Thomas A Sporn, Robin T Vollmer, Victor L Roggli.   

Abstract

Sarcomatoid mesothelioma is the least common, but most aggressive of the three major histological types of mesotheliomas. This study comprises 326 cases of sarcomatoid mesotheliomas among 2000 consecutive malignant mesothelioma cases received in consultation (16%). Patients included 312 men (96%) and 14 women (4%), with a median age of 70 years (range 41-94 years). Most tumors were pleural (319; 98%), and 7 were peritoneal (2%). Some desmoplastic features were identified in 110 cases (34%), and 70 (21%) were classified as desmoplastic. Rare subtypes included two cases with a lymphohistiocytoid pattern (<1%) and eight heterologous mesotheliomas (2%). Labeling for cytokeratins (CKs) was observed in 261/280 cases (93%), and for calretinin and vimentin in 31 and 91%, respectively. Pleural plaques were present in 79% of cases for which information was available, and asbestosis was diagnosed in 34/127 cases (27%). Median survival was 3.5 months. Fiber analysis was performed in 61 cases. The median asbestos body count was 1640/g wet lung tissue (by light microscopy). Amosite fibers were the most commonly identified fibers using energy-dispersive X-ray analysis and were significantly higher in the sarcomatoid cases, as were uncoated fibers using scanning electron microscopy. This study represents the largest series of sarcomatoid and desmoplastic malignant mesotheliomas to date and confirms the diagnostic usefulness of CK immunohistochemistry. The relationship with asbestos exposure--particularly amosite--and an association with pleural plaques and less often asbestosis is confirmed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20081811     DOI: 10.1038/modpathol.2009.180

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  28 in total

Review 1.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

2.  GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.

Authors:  Zheng Hua Piao; Xin Cheng Zhou; Jia Yi Chen
Journal:  Virchows Arch       Date:  2021-02-11       Impact factor: 4.064

3.  Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.

Authors:  Sara V Soldera; John Kavanagh; Melania Pintilie; Natasha B Leighl; Marc de Perrot; John Cho; Andrew Hope; Ronald Feld; Penelope A Bradbury
Journal:  Oncologist       Date:  2018-11-26

Review 4.  The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review.

Authors:  Greta Alì; Rossella Bruno; Gabriella Fontanini
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

5.  BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.

Authors:  Marta Cigognetti; Silvia Lonardi; Simona Fisogni; Piera Balzarini; Vilma Pellegrini; Andrea Tironi; Luisa Bercich; Mattia Bugatti; Giulio Rossi; Bruno Murer; Mattia Barbareschi; Silvia Giuliani; Alberto Cavazza; Gianpietro Marchetti; William Vermi; Fabio Facchetti
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

6.  The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma.

Authors:  Arun K Iyer; Yang Su; Jinjin Feng; Xiaoli Lan; Xiaodong Zhu; Yue Liu; Dongwei Gao; Youngho Seo; Henry F Vanbrocklin; V Courtney Broaddus; Bin Liu; Jiang He
Journal:  Biomaterials       Date:  2011-01-20       Impact factor: 12.479

7.  New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.

Authors:  F Galateau Salle; N Le Stang; A G Nicholson; D Pissaloux; A Churg; S Klebe; V L Roggli; H D Tazelaar; J M Vignaud; R Attanoos; M B Beasley; H Begueret; F Capron; L Chirieac; M C Copin; S Dacic; C Danel; A Foulet-Roge; A Gibbs; S Giusiano-Courcambeck; K Hiroshima; V Hofman; A N Husain; K Kerr; A Marchevsky; K Nabeshima; J M Picquenot; I Rouquette; C Sagan; J L Sauter; F Thivolet; W D Travis; M S Tsao; B Weynand; F Damiola; A Scherpereel; J C Pairon; S Lantuejoul; V Rusch; N Girard
Journal:  J Thorac Oncol       Date:  2018-04-30       Impact factor: 15.609

Review 8.  Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.

Authors:  Weiquan Zhang; Xinshu Wu; Licun Wu; Weidong Zhang; Xiaogang Zhao
Journal:  Ann Transl Med       Date:  2015-08

9.  Localized malignant pleural sarcomatoid mesothelioma misdiagnosed as benign localized fibrous tumor.

Authors:  Kwan-Chang Kim; Hong-Phuc Vo
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

10.  Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma.

Authors:  Krishna Pillai; Mohammad H Pourgholami; Terence C Chua; David L Morris
Journal:  Am J Cancer Res       Date:  2013-08-14       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.